Form 4: Elicio Therapeutics CSO Granted Equity Awards

Elicio Therapeutics' Chief Scientific Officer, Peter DeMuth, was granted 20,800 restricted stock units and options to purchase 41,600 shares of common stock.

Summary

• Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, Inc. (ELTX), acquired 20,800 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs were granted on February 2, 2026, at a price of $0 per share, indicating they are compensation grants.
• The RSUs will vest as to 25% on February 2, 2027, with the remaining vesting in annual installments over a three-year period thereafter, contingent on continued service.
• DeMuth also acquired options to purchase 41,600 shares of common stock with an exercise price of $8.1 per share.
• These stock options were granted on February 2, 2026, and will vest as to 25% on February 2, 2027, with the remainder vesting in monthly installments over a three-year period thereafter, also subject to continued service.
• The stock options have an expiration date of February 2, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with long-term shareholder value, without indicating any immediate operational or financial shifts.

Positives

• The equity grants align the Chief Scientific Officer's interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedules for both RSUs and stock options serve as a retention mechanism, encouraging Peter DeMuth's continued service to the company over several years.

Negatives

• The future conversion of RSUs into common stock and the exercise of stock options will result in a degree of share dilution for existing shareholders.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon Peter DeMuth's continued service to Elicio Therapeutics through the applicable vesting dates.

Future Outlook

The vesting schedules for the RSUs and stock options extend over a three-year period following the first anniversary of the grant date, indicating an expectation of Peter DeMuth's continued service and contribution to the company's future success.

Industry Context

StockSavvy.ai notes that equity compensation, including restricted stock units and stock options with multi-year vesting schedules, is a standard practice in the biotechnology and pharmaceutical industries. This approach is widely used to attract, retain, and motivate key scientific and executive talent, aligning their long-term financial incentives with the company's strategic goals and shareholder value creation.

Comparison to Industry Standards

• Equity grants, such as RSUs and stock options, are a common component of executive compensation packages across the biotech sector, similar to practices observed at companies like Moderna, BioNTech, and Regeneron Pharmaceuticals.
• The vesting schedule, with an initial 25% vesting after one year followed by subsequent annual or monthly installments over three years, is a typical structure designed to ensure long-term retention and performance alignment, consistent with industry benchmarks.
• The grant of options with an exercise price above $0 and RSUs at a $0 grant price reflects standard compensation practices for incentivizing future performance and retaining key personnel in growth-oriented industries.

Stakeholder Impact

• Shareholders: Potential for minor future dilution from the conversion and exercise of equity awards, balanced by the retention and incentivization of a key executive.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.
• Management: Peter DeMuth's compensation package is enhanced, providing strong incentives for continued performance and loyalty to the company.

Next Steps

• The RSUs will vest as to 25% on February 2, 2027, with remaining vesting annually over three years.
• The stock options will vest as to 25% on February 2, 2027, with remaining vesting monthly over three years.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key executive. While it aligns management's interests with shareholders and aids in retention, it does not present new information that would significantly alter the company's fundamental outlook or warrant a change in investment recommendation. It is a standard operational event for a publicly traded company.

Keywords

Elicio Therapeutics, ELTX, Peter DeMuth, Chief Scientific Officer, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Insider Transaction, Executive Compensation, Vesting Schedule